Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections

Dec 07 2011

• By Derrick Gingery

Related Content

Biosimilar User Fee Agreement Includes “Financial Hold” On Development Programs For Failure To Pay

Dec 06 2011

Generic User Fees: FDA Reaches Out To More Trade Groups; Plan Could Mix Inspection and Application Fees

Jan 03 2011

FDA Cloak And Dagger: GMP "Intelligence" Sought As Part Of Globalization Plan

Mar 15 2011

FDA’s Generic Drug Office Goes On Diet Before Swallowing User Fees

Nov 28 2011

FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues

Sep 26 2011

ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five

Sep 12 2011

Additional Topics

United States Regulation Manufacturing BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window